Quantcast

Latest glioblastoma multiforme Stories

2014-08-29 08:24:27

Investor update call to be held Tuesday, September 2 VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 29, 2014 /PR Newswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the Company") today announced the filing of June 30, 2014 fiscal year-end financial statements. The Company recently changed its fiscal year end to June 30th in order to facilitate an application to list its common stock on a national securities exchange in the timeliest manner possible. DelMar's...

2014-08-28 08:27:58

SAN ANTONIO, Aug. 28, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing prodrug therapeutics for the treatment of cancer, announces the recent publication of the article "Targeting thapsigargin towards tumors" in the journal Steroids. The recent article co-authored by Doan, et al. (see full reference below), reviews the evolution and development of GenSpera's prodrug technology platform that is designed to deliver the potent, cytotoxic activity of...

2014-08-27 23:05:24

Twelve Early Career Scientists Selected to Receive ABTA Basic Research Fellowships and Discovery Grant Award Chicago, IL (PRWEB) August 27, 2014 The American Brain Tumor Association is pleased to announce the recipients of the 2014-2016 Basic Research Fellowships and 2014-2015 Discovery Grant Awards. Through the funding of early career scientists, the ABTA is seeding the field with talented, bright young investigators who have the potential to change our understanding of the causes,...

2014-08-27 23:02:42

NovoTTF™-100A System Offers Novel, Non-Invasive Treatment in Fight Against an Aggressive Type of Brain Cancer Morristown,NJ (PRWEB) August 27, 2014 ANS is pleased to announce the availability of NovoTTF-100A System, a ground breaking anti-cancer therapy for the treatment of recurrent glioblastoma (GBM). Experts at ANS are now certified to prescribe this new medical therapy and will begin extending this new treatment option for recurrent GBM patients starting immediately. NovoTTF™...

2014-08-27 16:25:38

DelMar Is Advancing Clinical Trials With VAL-083 As A New Chemotherapy For Refractory Glioblastoma Multiforme VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 27, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc., (OTCQB: DMPI), developer of advanced cancer therapeutics, will be featured as a presenting company at the 16th Annual Rodman & Renshaw Global Investment Conference, sponsored by H.C. Wainwright & Co., LLC. The presentation will take place Tuesday, September...

2014-08-21 23:09:06

Researchmoz.us added deep and professional market research reports on "Global and China Power Battery Management System (BMS) Industry Report, 2014-2017" Market Analysis and Overview. Albany, NY (PRWEB) August 21, 2014 BMS is a key component of electric vehicles and hybrid vehicles. To ensure safe and reliable operation of batteries, BMS needs to have various functions such as battery status monitoring and assessment, charging and discharging control, balancing and so forth. To...

2014-08-21 23:07:25

MarketResearchReports.Biz include new market research report "Glioblastoma Multiforme Therapeutics In Asia-Pacific Markets To 2020 - Novel Therapeutic Approaches Target High Unmet Need In Newly Diagnosed And Recurrent GBM" to its huge collection of research reports. View all Therapeutic Area Market Research Reports at http://www.marketresearchreports.biz/category/37. Albany, NY (PRWEB) August 21, 2014 Glioblastoma Multiforme Therapeutics in Asia-Pacific Markets to 2020 - Novel...

2014-08-21 08:28:35

Japanese Society of Neuro-Oncology calls for rapid approval by the Japanese Ministry of Health and Welfare (MHLW) ST. HELIER, Jersey, Aug. 21, 2014 /PRNewswire/ -- Novocure, a commercial stage oncology company, announced today that it has submitted the registration dossier for Pre-Market Approval (PMA) of the NovoTTF-100A System to treat recurrent glioblastoma to the Japanese Pharmaceutical and Medical Device Agency (PMDA). Glioblastoma is the most common and deadly form of primary...

2014-08-19 16:29:08

Funding To Increase Manufacturing Capacity for Ramp-Up of Programs BETHESDA, Md., Aug. 19, 2014 /PRNewswire/ -- Northwest Biotherapeutics (NASDAQ: NWBO) (NW Bio), a biotechnology company developing DCVax® personalized immune therapies for solid tumor cancers, announced today that the $17.5 million convertible note offering announced last Thursday, August 14, 2014, has closed. The three-year notes have a 5% interest rate and are convertible at $7.30 per share of common stock. The...

2014-08-19 08:29:50

VAL-083 Phase I/II VAL-083 clinical trial advances to 50mg/m(2) cohort VANCOUVER, British Columbia and MENLO PARK, Calif., Aug. 19, 2014 /PRNewswire/ -- DelMar Pharmaceuticals, Inc. (OTCQB: DMPI) ("DelMar" "the company") announced today a protocol amendment to allow for expanded dosing in its VAL-083 clinical trial had been filed with the U.S. Food and Drug Administration (FDA) and that a new cohort of a new 50mg/m(2) has been opened at three clinical trial sites in the United...


Word of the Day
bodacious
  • Remarkable; prodigious.
  • Audacious; gutsy.
  • Completely; extremely.
  • Audaciously; boldly.
  • Impressively great in size; enormous; extraordinary.
This word is probably from the dialectal 'boldacious,' a blend of 'bold' and 'audacious.'
Related